User profiles for M. Levis
Mark LevisProfessor of Oncology, Johns Hopkins University Verified email at jhmi.edu Cited by 27245 |
[HTML][HTML] Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, …
genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, …
FLT3: ITDoes matter in leukemia
FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the
development of the hematopoietic and immune systems. Activating mutations of FLT3 are now …
development of the hematopoietic and immune systems. Activating mutations of FLT3 are now …
[HTML][HTML] Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement
…, FJ Kaiser, G Koekkoek, M Levis, M Mariani… - Nature Reviews …, 2018 - nature.com
Cornelia de Lange syndrome (CdLS) is an archetypical genetic syndrome that is characterized
by intellectual disability, well-defined facial features, upper limb anomalies and atypical …
by intellectual disability, well-defined facial features, upper limb anomalies and atypical …
[HTML][HTML] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
…, N Hasabou, X Liu, E Bahceci, MJ Levis - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations
in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage …
in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage …
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith, M Levis, M Beran, F Giles, H Kantarjian… - Blood, 2004 - ashpublications.org
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30%
of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure …
of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure …
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
…, KG Sprankle, HK Patel, M Levis… - Blood, The Journal …, 2009 - ashpublications.org
Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately
30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease …
30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease …
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
…, RY Wang, X Ling, O Frolova, M Levis… - Blood, The Journal …, 2009 - ashpublications.org
SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment
interactions. We previously reported that bone marrow–derived stromal cells inhibit …
interactions. We previously reported that bone marrow–derived stromal cells inhibit …
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Effective targeted cancer therapeutic development depends upon distinguishing disease-associated
‘driver’ mutations, which have causative roles in malignancy pathogenesis, from ‘…
‘driver’ mutations, which have causative roles in malignancy pathogenesis, from ‘…
The long-run performance of initial public offerings: The UK experience 1980-1988
M Levis - Financial management, 1993 - JSTOR
… Like the FTA, this is als weighted index; it comprises the lowest ten per capitalization of the
Main and USM equity m about 1,600 firms - and is rebalanced annually. A the HGSC Index is …
Main and USM equity m about 1,600 firms - and is rebalanced annually. A the HGSC Index is …
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
M Levis, F Ravandi, ES Wang, MR Baer… - Blood, The Journal …, 2011 - ashpublications.org
… mitoxantrone 8 mg/m 2 per day, etoposide 100 mg/m 2 , and cytarabine 1000 mg/m 2 per day
… 24 months received HiDAC, consisting of cytarabine 1500 mg/m 2 daily on days 1 to 5. For …
… 24 months received HiDAC, consisting of cytarabine 1500 mg/m 2 daily on days 1 to 5. For …